logo

CMPS

COMPASS Pathways·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CMPS fundamentals

COMPASS Pathways (CMPS) released its earnings on Nov 4, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -1.44 (YoY -157.14%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-1.44
-157.14%
Report date
Nov 4, 2025
CMPS Earnings Call Summary for Q3,2025
  • 9-12 Month Launch Acceleration: FDA-supported rolling NDA submission and completed Phase III enrollment drive 9-12 month timeline reduction.
  • Commercial Readiness: 6,000+ SPRAVATO-capable sites primed for COMP360, with REMS mirroring SPRAVATO protocols.
  • Financial Stability: $186M cash on hand, maintaining runway to 2027; Q3 cash used: $35M, full-year guidance: $120-145M.
  • PTSD Trial Progress: Protocol finalized, targeting Q1 2026 first patient enrollment.
EPS
Revenue

Revenue & Expenses

Key Indicators

COMPASS Pathways (CMPS) key financial stats and ratios, covering profitability, financial health, and leverage.
COMPASS Pathways (CMPS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
COMPASS Pathways (CMPS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
COMPASS Pathways (CMPS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does COMPASS Pathways (CMPS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track COMPASS Pathways (CMPS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield